SRI-286, a thiosemicarbazole, in combination with mefloquine and moxifloxacin for treatment of murine Mycobacterium avium complex disease
SRI-286, a thiosemicarbazole, in combination with mefloquine and moxifloxacin for treatment of murine Mycobacterium avium complex disease
复制标题
DOI：
10.1128/aac.48.9.3556-3558.2004
复制
发表时间：
2004-09-01
影响因子：
4.9
通讯作者：
Young, LS
中科院分区：
文献类型：
--
作者：
Bermudez, LE;Kolonoski, P;Young, LS
当大环内酯产生耐药性时，鸟分枝杆菌病的治疗仍然具有挑战性。我们感染C57米色小鼠，用甲氟喹、ri -286和莫西沙星治疗。SRI-286 （80 mg/kg）对肝脏有杀菌作用。甲氟喹联合莫西沙星或甲氟喹联合SRI-286治疗效果优于单用甲氟喹。
Treatment of Mycobacterium avium disease remains challenging when macrolide resistance develops. We infected C57 beige mice and treated them with mefloquine, SRI-286, and moxifloxacin. SRI-286 (80 mg/kg) was bactericidal in the liver. Mefloquine plus moxifloxacin or mefloquine plus SRI-286 were better than mefloquine alone.